
    
      The MTD for the Day 1 21-Day schedule was defined at the 0.45 mg/m2 dose level. The study was
      terminated prior to full enrollment of the colorectal cancer (CRC) expansion cohort, due to a
      lack of demonstrated activity resulting in Principal Investigator (PI) loss interest to
      continue enrollment. Collection of all outstanding data is ongoing and database lock is
      estimated to be complete in June 2008.
    
  